Skip to content
OncLive® On Air cover art

All episodes

OncLive® On Air, 500 episodes. Page 2 of 5.

#
Title
101

S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

102

S17 Ep25: TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

103

S17 Ep24: Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

104

S17 Ep22: Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD

105

S17 Ep23: FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD

106

S17 Ep21: Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond

107

S17 Ep20: Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

108

S17 Ep19: Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

109

S17 Ep18: Metastatic Bladder Cancer 2026 UPDATE

110

S17 Ep16: Show Me the Data®: From Mutation to Action—KRAS as a Therapeutic Target in PDAC

111

S17 Ep15: FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

112

S17 Ep14: Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

113

S17 Ep13: Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

114

S17 Ep12: ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD

115

S17 Ep11: Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

116

S17 Ep10: Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

117

S17 Ep9: Medical Crossfire®: Optimizing ESR1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

118

S17 Ep17: Localized Bladder Cancer 2026 UPDATE

119

S17 Ep8: From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into Practice

120

S17 Ep7: RAS/MAP Kinase Pathway Targeting Makes Strides in Gynecologic Cancer Management: With Ursula A. Matulonis, MD; and Elizabeth H. Stover, MD, PhD

121

S17 Ep6: Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies

122

S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

123

S17 Ep4: Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

124

S17 Ep3: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast Cancer

125

S17 Ep2: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

126

S17 Ep1: Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application

127

S16 Ep50: Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

128

S16 Ep49: Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

129

S16 Ep48: Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes

130

S16 Ep47: The Intricacies of Approved Therapies Pose Questions for CLL Management: With Mazyar Shadman, MD, MPH

131

S16 Ep46: Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

132

S16 Ep45: Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

133

S16 Ep44: Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

134

S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD

135

S16 Ep41: The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA

136

S17 Ep72: HIF-2 Targeting Is Set to Transform Kidney Cancer Management: With Chandler Park, MD; and Katy Beckermann, MD

137

S16 Ep37: Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

138

S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

139

S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD–Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD

140

S16 Ep39: Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD

141

S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

142

S16 Ep36: New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

143

S16 Ep35: T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD

144

S16 Ep34: Utilizing Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

145

S16 Ep33: Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD

146

S16 Ep32: ASCO GU 2026 Takeaways

147

S16 Ep31: ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD

148

S16 Ep30: ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD

149

S16 Ep29: Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

150

S16 Ep28: Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

151

S16 Ep26: Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD

152

S16 Ep27: Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

153

S16 Ep25: Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions

154

S16 Ep24: Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

155

S16 Ep23: Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

156

S16 Ep22: Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI

157

S16 Ep21: FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO

158

S16 Ep20: Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

159

S16 Ep20: Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD

160

S16 Ep19: Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC

161

S16 Ep18: Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD

162

S16 Ep17: Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD

163

S16 Ep16: Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma

164

S16 Ep15: Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD

165

S16 Ep14: Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD

166

S16 Ep13: Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD

167

S16 Ep11: Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

168

S16 Ep12: Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH

169

S16 Ep11: Treatment Evolutions Affect First-Line Chemotherapy Selection in Metastatic Pancreatic Cancer: With Rachna T. Shroff, MD, MS, FASCO; and Kristen Spencer, DO

170

S16 Ep10: Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

171

S16 Ep9: A Thoracic Oncologist’s Journey from Iran to Innovation: With Girindra Raval, MD; and Hossein Borghaei, DO, MS

172

S16 Ep8: ASCO GU 2026 Preview

173

S16 Ep7: Answering Common Questions About Chondrosarcoma Diagnosis and Management: With Hari Desphande, MD, and Philippos Costa, MD

174

S16 Ep6: FDA Approval Insights: Subcutaneous Amivantamab for EGFR-Mutated NSCLC: With Alexander I. Spira, MD, PhD, FACP, FASCO

175

S16 Ep5: Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

176

S16 Ep4: Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD

177

S16 Ep3: Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD

178

S16 Ep2: “D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

179

S16 Ep1: Targeted Therapies Take Center Stage for Estrogen Receptor–Positive Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

180

S15 Ep50: Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

181

S15 Ep49: Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH

182

S15 Ep48: Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

183

S15 Ep47: ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

184

S15 Ep46: Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

185

S15 Ep45: Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD

186

S15 Ep44: Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

187

S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer

188

S15 Ep42: Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD

189

S15 Ep41: Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP

190

S15 Ep40: ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

191

S15 Ep39: Novel Targeted Agents Are Poised to Influence MPN Treatment Paradigm: With John O. Mascarenhas, MD

192

S15 Ep38: Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

193

S15 Ep37: Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

194

S15 Ep36: Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

195

S15 Ep35: Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2– Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

196

S15 Ep34: Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

197

S15 Ep33: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

198

S15 Ep32: Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD

199

S15 Ep31: Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

200

S15 Ep30: Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms